This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Is Divalproex a Cost Effective Alternative in the Acute and Prophylactic Treatment of Bipolar I Disorder?

Roland M. Dardennes and Christian Even

Published: November 15, 1997

Article Abstract

Letter to the Editor

Sir: A recent pharmacoeconomic study concluded that divalproex
is a less costly treatment than lithium in the acute and
prophylactic treatment of patients with bipolar I disorder.

Such a decision-analytic study must rest on hard data, and
hard data supporting the prophylactic properties of divalproex
are unavailable. The authors did mention that no controlled
study assessed the prophylactic efficacy of divalproex, and, to
our knowledge, no such study has been published since then.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 58

Quick Links: